The DOI matches its Crossref record; 166 of the 166 references it cites were found in a registry or an index.
Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease
Abstract
Venous thromboembolic disorders form a spectrum of conditions characterized by in situ thrombus formation and the variable presence of embolic manifestations. The clinical presentation depends to a large extent on the site and extent of thrombus formation and on the underlying cause. In the absence of genetic deficiencies, thrombosis occurs in the older population, largely in the context of marked environmental influences such as surgery, obesity, and underlying malignancy. In contrast, at the other extreme, familial thrombosis associated with mutations in genes for protein S, protein C, or antithrombin is associated with younger age of onset, lesser environmental stimulus, and thrombus formation often in unusual sites. There is an increasing awareness of the importance of hemostatic mechanisms in the pathogenesis of venous thrombosis. The hemostatic process comprises coagulation and fibrinolytic systems with activators, zymogens, cofactors, surfaces (such as platelets), and inhibitors. The function and regulation of these composite systems and factors have been extensively studied. Understanding their functional integration in vivo, however, still presents a major challenge. A starting point for a simplified model of integration envisages a balance between procoagulant (clot-promoting) and anticoagulant (clot-preventing) mechanisms. This balance serves to prevent an explosive generation of thrombin when coagulation is triggered. The balance is determined by the (functional) levels of all coagulation and fibrinolytic factors, with increases in the levels of coagulation factors and decreases in the levels of both fibrinolytic factors and natural inhibitors being procoagulant. The role of inhibitory mechanisms in preventing venous occlusion was established after the identification of the link between inherited deficiencies of antithrombin, protein C, protein S, and venous thrombosis during the 1960s and the 1970s. The general importance of the anticoagulant pathway involving protein C and protein S was established by the widespread prevalence among white populations and the clinical consequences of the phenotype of activated protein C resistance (APCR) and its main causative gene mutation, factor V G1691A (factor V Arg506Gln, factor V Leiden). There has been slower appreciation of the procoagulant effect of increased levels of coagulation factors in venous disease, but recent work has highlighted the likely importance of prothrombin and factor VIII levels in this regard.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutation in blood coagulation factor V associated with resistance to activated protein C
Bertina, R. M., Koeleman, B. P. C., Koster, T., Rosendaal, F. R., Dirven, R. J., de Ronde, H., van der Velden, P. A., & Reitsma, P. H. (1994) · Nature · doi:10.1038/369064a0 · Cited by 3,783
Boushey, C. J. (1995) · JAMA · doi:10.1001/jama.1995.03530130055028 · Cited by 3,584
Poort, Sr., Rosendaal, F., Reitsma, P., & Bertina, R. (1996) · Blood · doi:10.1182/blood.v88.10.3698.bloodjournal88103698 · Cited by 3,079
Dahlbäck, B., Carlsson, M., & Svensson, P. J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.3.1004 · Cited by 1,945
Meade, T. W., Brozovic, M., Chakrabarti, R. R., Haines, A. P., Imeson, J. D., Mellows, S., Miller, G. J., North, W. R. S., Stirling, Y., & Thompson, S. G. (1986) · The Lancet · doi:10.1016/s0140-6736(86)90111-x · Cited by 1,939
Thompson, S. G., Kienast, J., Pyke, S. D. M., Haverkate, F., & van de Loo, J. C. W. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321003 · Cited by 1,821
Plasma Homocysteine as a Risk Factor for Vascular Disease: The European Concerted Action Project
Graham, I. M. (1997) · JAMA · doi:10.1001/jama.1997.03540460039030 · Cited by 1,738
Fibrinogen as a Risk Factor for Stroke and Myocardial Infarction
Wilhelmsen, L., Svärdsudd, K., Korsan-Bengtsen, K., Larsson, B., Welin, L., & Tibblin, G. (1984) · New England Journal of Medicine · doi:10.1056/nejm198408233110804 · Cited by 1,646
Venous thrombosis: a multicausal disease
Rosendaal, F. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10266-0 · Cited by 1,576
PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION
Hamsten, A., Walldius, G., Szamosi, A., Blombäck, M., Faire, U., Dahlén, G., Landou, C., & Wiman, B. (1987) · The Lancet · doi:10.1016/s0140-6736(87)93050-9 · Cited by 1,474
Cited by
Alternative cleavage and polyadenylation in health and disease
Gruber, A. J., & Zavolan, M. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0145-z · Cited by 472
Basic mechanisms and pathogenesis of venous thrombosis
Esmon, C. T. (2009) · Blood Reviews · doi:10.1016/j.blre.2009.07.002 · Cited by 449
Cines, D. B., Lebedeva, T., Nagaswami, C., Hayes, V., Massefski, W., Litvinov, R. I., Rauova, L., Lowery, T. J., & Weisel, J. W. (2014) · Blood · doi:10.1182/blood-2013-08-523860 · Cited by 420
Ye, Z., Liu, E. H., Higgins, J. P., Keavney, B. D., Lowe, G. D., Collins, R., & Danesh, J. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68263-9 · Cited by 411
Winkelmann, B. R., März, W., Boehm, B. O., Zotz, R., Hager, J., Hellstern, P., & Senges, J. (2001) · Pharmacogenomics · doi:10.1517/14622416.2.1.s1 · Cited by 368
Metadata
- Authors
- Lane, D. A., & Grant, P. J.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2000-03-01
- Volume
- 95
- Issue
- 5
- Pages
- 1517-1532
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W176430369
- Cited by
- 495
- References
- 166
- FWCI
- 25.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. https://app.cochat.ai/papers/10.1182/blood.v95.5.1517.005k48_1517_1532
- The paper
- Lane, D. A., & Grant, P. J. (2000). Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood. https://doi.org/10.1182/blood.v95.5.1517.005k48_1517_1532
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.